Quote:Jemperli is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDAapproved test, that has progressed on or following prior treatment with a platinumcontaining regimen
the GARNET trial took place between 2017 and 2019.
I am astonished, as you are, by the approval in response to a Phase I. All I was saying was that so far as I know, a company still has to file an NDA or BLA. In this case the approval was granted four years after that Phase I trial began.
Haven't checked the timeframe of the other trials Sherlock has mentioned, but this one, at least, was no overnight sensation. But yes, it was based on a Phase I trial. I agree that this is amazing.